Search research articles
Contact Us
Filters
Showing results (81-90 of 133) with videos related to
Page
of 14
Sort By:
Mabs
|
September 26, 2012
IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA
John Marquardt, Richard H J Begent, Kerry Chester, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
October 30, 2012
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
Jiping Zhang, Matthildi Valianou, Heidi Simmons, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
Michael B Atkins, David Carbone, George Coukos, et al.
Cancer Immunology Research
|
December 20, 2018
A Mechanism of Resistance to Antibody-Targeted Immune Attack
Dalal S Aldeghaither, David J Zahavi, Joseph C Murray, et al.
Molecular Cancer Therapeutics
|
October 19, 2012
Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production
Michelle K Gleason, Michael R Verneris, Deborah A Todhunter, et al.
Scientific Reports
|
April 11, 2018
Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis
Hongyan Yuan, Xiaoyi Wang, Chunmei Shi, et al.
Cancer Chemotherapy and Pharmacology
|
October 3, 2002
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
Nancy L Lewis, Richard Scher, James M Gallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2004
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
Jonathan D Cheng, James S Babb, Corey Langer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2020
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Michael J Pishvaian, Hongkun Wang, Aiwu Ruth He, et al.
Bio-Protocol
|
December 19, 2017
RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells
Yong-Wei Zhang, Rochelle E Nasto, Sandra A Jablonski, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 133) with videos related to
Sort By:
Page
of 14
Mabs
|
September 26, 2012
IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA
John Marquardt, Richard H J Begent, Kerry Chester, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
October 30, 2012
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
Jiping Zhang, Matthildi Valianou, Heidi Simmons, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
Michael B Atkins, David Carbone, George Coukos, et al.
Cancer Immunology Research
|
December 20, 2018
A Mechanism of Resistance to Antibody-Targeted Immune Attack
Dalal S Aldeghaither, David J Zahavi, Joseph C Murray, et al.
Molecular Cancer Therapeutics
|
October 19, 2012
Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production
Michelle K Gleason, Michael R Verneris, Deborah A Todhunter, et al.
Scientific Reports
|
April 11, 2018
Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis
Hongyan Yuan, Xiaoyi Wang, Chunmei Shi, et al.
Cancer Chemotherapy and Pharmacology
|
October 3, 2002
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
Nancy L Lewis, Richard Scher, James M Gallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2004
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
Jonathan D Cheng, James S Babb, Corey Langer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2020
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Michael J Pishvaian, Hongkun Wang, Aiwu Ruth He, et al.
Bio-Protocol
|
December 19, 2017
RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells
Yong-Wei Zhang, Rochelle E Nasto, Sandra A Jablonski, et al.
Page
of 14